SEC Filing · 3
Obsidian Therapeutics, Inc.
OBXNASDAQEQUITYCurrent
SEC Filing
Company context
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian’s proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian has offices in Cambridge and Bedford, MA. For more information, please visit www.obsidiantx.com.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗